GUMDROP : UMD - Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Created by Nancy Dawson, last modified on Jun 25, 2013
Description:This is a randomized, open-label Phase 2 clinical trial to evaluate whether suppression of Hsp27 (Heat shock protein 27) production using OGX-427, a second-generation antisense oligonucleotide (ASO), in combination with docetaxel can prolong survival time compared to docetaxel alone in participants with locally advanced or metastatic urothelial carcinoma (UC) that are relapsed or refractory after receiving a platinum-containing regimen.
Link:http://clinicaltrials.gov/ct2/show/NCT01780545
Site:University of Maryland
Principal Investigator:Arif Hussain, MD